Literature DB >> 11914999

Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.

Kent A Sepkowitz1.   

Abstract

In the next decade, longer survival of patients with cancer and more-aggressive therapies applied to common conditions, such as asthma and rheumatoid arthritis, will result in a larger population with significant immune system defects. Many in this population will be at risk for opportunistic infections, which are familiar to doctors who have treated people infected with human immunodeficiency virus (HIV). However, the epidemiology, presentation, and outcome of these infections in patients with an immune system defect, other than that caused by HIV infection, may be different than those encountered in patients with acquired immunodeficiency syndrome. Reviewed are 4 common opportunistic infections: Pneumocystis carinii pneumonia, cryptococcosis, atypical mycobacterial infection, and cytomegalovirus infection. Emphasized are the important differences among these groups at risk.

Entities:  

Mesh:

Year:  2002        PMID: 11914999     DOI: 10.1086/339548

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  124 in total

1.  69-year-old woman with dyspnea and cough productive of white sputum.

Authors:  Karna K Sundsted; Husnain Syed; M Caroline Burton
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

2.  Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation.

Authors:  Steven Gabardi; Sushrut S Waikar; Spencer Martin; Keri Roberts; Jie Chen; Lea Borgi; Hussein Sheashaa; Christine Dyer; Sayeed K Malek; Stefan G Tullius; Nidyanandh Vadivel; Monica Grafals; Reza Abdi; Nader Najafian; Edgar Milford; Anil Chandraker
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

3.  Mustard seed agar, a new medium for differentiation of Cryptococcus neoformans.

Authors:  B Nandhakumar; C P Girish Kumar; D Prabu; Thangam Menon
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

4.  Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.

Authors:  Jesse Wells; Constantine G Haidaris; Terry W Wright; Francis Gigliotti
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Downregulation of PU.1 leads to decreased expression of Dectin-1 in alveolar macrophages during Pneumocystis pneumonia.

Authors:  Chen Zhang; Shao-Hung Wang; Chung-Ping Liao; Shoujin Shao; Mark E Lasbury; Pamela J Durant; Chao-Hung Lee
Journal:  Infect Immun       Date:  2010-01-11       Impact factor: 3.441

6.  Clinical Performance of (1,3) Beta-D Glucan for the Diagnosis of Pneumocystis Pneumonia (PCP) in Cancer Patients Tested With PCP Polymerase Chain Reaction.

Authors:  Sejal Morjaria; John Frame; Alexandra Franco-Garcia; Alexander Geyer; Mini Kamboj; N Esther Babady
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

Review 7.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

Review 8.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

9.  Red fist and muscle weakness with a rare complication.

Authors:  Iris van Groeningen; Joyce Arnoldus; Roos Perenboom; Alexandre Voskuyl
Journal:  BMJ Case Rep       Date:  2014-02-20

10.  Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis.

Authors:  Michael J Plakke; Leena Jalota; Benjamin J Lloyd
Journal:  BMJ Case Rep       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.